Publication: Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?
1
Issued Date
2015-04-01
Resource Type
ISSN
15276473
15276465
15276465
DOI
Other identifier(s)
2-s2.0-84925866791
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Liver Transplantation. Vol.21, No.4 (2015), 539-546
Suggested Citation
Jackrapong Bruminhent, Charat Thongprayoon, Ross A. Dierkhising, Walter K. Kremers, Elitza S. Theel, Raymund R. Razonable Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?. Liver Transplantation. Vol.21, No.4 (2015), 539-546. doi:10.1002/lt.24078 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36476
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?
Other Contributor(s)
Abstract
© 2015 AASLD. © 2015 American Association for the Study of Liver Diseases. Despite preexisting cytomegalovirus (CMV) immunity, CMV-seropositive liver transplantation (LT) patients remain at risk of CMV infection. We hypothesized that the pre-transplant CMV antibody titer correlates with the risk of CMV reactivation. We conducted a retrospective study of CMV-seropositive LT recipients who did not receive anti-CMV prophylaxis from 2007 to 2013. The pre-transplant CMV immunoglobulin G (IgG) titer, which was measured with an enzyme-linked fluorescent immunoassay, was assessed as a risk factor for CMV reactivation with multivariate Cox proportional hazards models. The population consisted of 225 CMV-seropositive LT patients with a median age of 57 years (interquartile range, 47-62 years). The CMV titer distributions were as follows: <60 (40%) and ≥60 AU/mL (60%). The Kaplan-Meier estimates for CMV infection were 17% at 3 months, 18% at 6 months, and 19% at 12 months after transplantation. In a univariate analysis, a marginally significant increased risk of CMV infection was seen in LT recipients with a pre-transplant CMV IgG titer<60 AU/mL versus≥60 AU/mL [hazard ratio (HR), 1.79; 95% confidence interval (CI), 0.98-3.28 (P = 0.06)]. This risk was statistically significant in the subgroup of recipients who received allografts from CMV-seropositive donors [HR, 2.21; 95% CI, 1.15-4.26 (P = 0.02)]. In a multivariate analysis, a pre-transplant CMV IgG titer<60 AU/mL was significantly associated with CMV infection [HR, 3.11; 95% CI, 1.60-6.03 (P<0.001)]. The other risk factors were high body mass index, donor CMV seropositivity, prolonged cold ischemic time, use of an interleukin-2 receptor antagonist for induction therapy, and high numbers of post-transplant infections. A lower pre-transplant CMV antibody titer is significantly associated with CMV infection after LT. Quantitative measurement of CMV-specific humoral immunity may have a potential role in improving the CMV prevention strategy in CMV-seropositive LT recipients. Liver Transpl 21:539-546, 2015.